ArticleBMC psychiatry2025
Plasma Lyso-PE 22:6 and Lyso-PE 20:4 are associated with development of mild to moderate depression revealed by metabolomics: a pilot study.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMild to moderate depression (MMD), as an early stage of depression, has a high incidence and may progress to severe depression, even leading to suicide. The lack of effective screening and treatment is due to the unknown metabolic changes and processes in patients with MMD. Here, we performed metabolite profiling to investigate the key metabolites associated with MMD in plasma.
methodsA high-throughput metabolomics method using ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) was used to determine the metabolic profiles of patients with MMD. Metabolic network analysis and machine learning models were used to screen and assess potential biomarkers of MMD.
resultsForty altered metabolites were identified between patients with MMD and healthy controls, which were mainly involved in seven metabolic pathways associated with amino acid and lipid metabolism. A metabolite-target-disease network was constructed to screen six metabolites as potential key metabolites most relevant to the onset of depression. Furthermore, 12 of the 40 metabolites were found to have a strong linear correlation with scores on the Hamilton depression scale. By combining network analysis with linear correlation, we identified lysophosphatidylethanolamine (Lyso-PE) 22:6 and Lyso-PE 20:4 as being associated with the development of depression. These two metabolites showed potential in distinguishing patients with MMD from healthy controls and exhibited different correlations with other key metabolites.
conclusionOur findings suggest that Lyso-PE 22:6 and Lyso-PE 20:4 are associated with the development of depression, indicating their potential use in future screening applications to prevent the progression of depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.